Please use this identifier to cite or link to this item: http://hdl.handle.net/10366/134304
MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL: Profile on PlumX
Title: MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
Authors: Rodríguez Vicente, Ana
Quwaider, Dalia
Benito Sánchez, Rocío
Misiewicz, Irena
Hernández Sánchez, María
García, Alfonso
Fisac, Rosa
Alonso, José
Zato Domínguez, Carolina
Paz Santana, Juan Francisco de
García, Juan
Sarasquete, M. Eugenia
Hernández, José Ángel
Corchado Rodríguez, Juan M.
González, Marcos
Gutiérrez, Norma
Hernández Rivas, Jesús M.
Keywords: Computer Science
Issue Date: 2015
Publisher: Springer Science + Business Media
Citation: BMC Cancer. Volumen 15 (1), pp. 238. Springer Science + Business Media.
Abstract: Background MicroRNAs are known to inhibit gene expression by binding to the 3′UTR of the target transcript. Downregulation of miR-223 has been recently reported to have prognostic significance in CLL. However, there is no evidence of the pathogenetic mechanism of this miRNA in CLL patients. Methods By applying next-generation sequencing techniques we have detected a common polymorphism (rs2307842), in 24% of CLL patients, which disrupts the binding site for miR-223 in HSP90B1 3′UTR. We investigated whether miR-223 directly targets HSP90B1 through luciferase assays and ectopic expression of miR-223. Quantitative real-time polymerase chain reaction and western blot were used to determine HSP90B1 expression in CLL patients. The relationship between rs2307842 status,HSP90B1 expression and clinico-biological data were assessed. Results HSP90B1 is a direct target for miR-223 by interaction with the putative miR-223 binding site. The analysis in paired samples (CD19+ fraction cell and non-CD19+ fraction cell) showed that the presence of rs2307842 and IGHV unmutated genes determined HSP90B1 overexpression in B lymphocytes from CLL patients. These results were confirmed at the protein level by western blot. Of note, HSP90B1 overexpression was independently predictive of shorter time to the first therapy in CLL patients. By contrast, the presence of rs2307842 was not related to the outcome. Conclusions HSP90B1 is a direct target gene of miR-223. Our results provide a plausible explanation of why CLL patients harboring miR-223 downregulation are associated with a poor outcome, pointing out HSP90B1 as a new pathogenic mechanism in CLL and a promising therapeutic target. Keywords Chronic lymphocytic leukemia MicroRNAs Next-generation sequencing
URI: http://hdl.handle.net/10366/134304
ISSN: 1471-2407 (Print)
Appears in Collections:Documentos OpenAire (Open Access Infrastructure for Research in Europe)
BISITE. Artículos de revista

Files in This Item:
File Description SizeFormat 
s12885-015-1212-2.pdf1,05 MBAdobe PDFThumbnail
View/Open


This item is is subject to a Creative Commons License